Hansa Biopharma Interim Report January-September 2023
• Encouraging high-level results for first-in-human trial of HNSA-5487• Well attended Hansa-sponsored symposium at ESOT focusing on first patient experiences• Dr. Hitto Kaufmann appointed new CSOLund, Sweden, October 26, 2023, Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and interim report for January to September 2023. Highlights for the third quarter of 2023 · Total Q3 revenue of SEK 22.8m including SEK 16.5m in product sales and SEK 5.7m under our agreement with Sarepta ·